Endpoints News reports an exclusive conversation with Anthropic’s Nathan Frey about biopharma partnerships, M&A activity, and pipeline implications tied to his experience bridging AI and drug discovery. Frey, previously a machine-learning scientist at Genentech and now leading drug discovery and development research at Anthropic, discussed how recent AI developments are translating into collaboration models. Frey also reflected on his pathway into AI for biotech after Anthropic’s acquisition of his startup Coefficient Bio earlier this year. The interview positions him to assess where partnerships and deals can accelerate computational chemistry and molecular design. For biotech professionals, the key takeaway is that large AI labs are not only building models, but actively shaping how they integrate into biopharma workflows through partnerships and acquisitions. The conversation is likely to interest teams evaluating how to partner with frontier AI capabilities while managing data, IP, and operational constraints.